<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="91334b92-a362-4d06-8373-035d413703a0"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Bromfenac Ophthalmic Solution safely and effectively.  See full prescribing information for bromfenac. <br/>Initial U.S. Approval: 1997</title>
   <effectiveTime value="20180108"/>
   <setId root="e853723e-8419-4444-89e9-ee3f571b0974"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="101196749" root="1.3.6.1.4.1.519.1"/>
            <name>Hi-Tech Pharmacal Co., Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="101196749" root="1.3.6.1.4.1.519.1"/>
                        <name>Hi-Tech Pharmacal Co., Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="50383-249" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="8e7af0a9-12f0-42e1-b87f-f404e5c9f7f7"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20180108"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="50383-249" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>bromfenac</name>
                        <formCode code="C60992" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION/ DROPS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>bromfenac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="1.035"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8ECV571Y37" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BROMFENAC SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="864P0921DW" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BROMFENAC</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="91MBZ8H3QO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM BORATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VTK01UQK3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM SULFITE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1.7"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="50383-249-71" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20140122"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA203395" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20140122"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>clear, yellow to orange yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_943813c6-26c0-48e6-9325-eb1358b597bf">
               <id root="736ee03a-51e8-445f-96f7-9299f6b1ac76"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Bromfenac Ophthalmic Solution 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.</paragraph>
               </text>
               <effectiveTime value="20110505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction <content styleCode="bold">(1)</content>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_eaa8e38f-91b6-42f7-837d-cd7c198780c7">
               <id root="b6c0f5a8-bdc0-462a-9ef3-671204ae5a42"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20121228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery and through the first 14 days post-surgery  <content styleCode="bold">(2.1)</content>.  </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_section_id_78a3c336-a0de-4d17-a9a8-a20619bc2722">
                     <id root="2c1aeedd-740c-48ba-a8cc-21e79765b96f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosing</title>
                     <text>
                        <paragraph>For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one drop of bromfenac ophthalmic solution should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.</paragraph>
                     </text>
                     <effectiveTime value="20121228"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_c974e601-3f19-481d-bdf4-fed1d12968f1">
                     <id root="cc4cdc05-5ad8-4bde-b59a-d7d723df534d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Use with Other Topical Ophthalmic Medications</title>
                     <text>
                        <paragraph>Bromfenac ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_form_strength_id_b56a8c6b-55e7-46af-8776-a42356aa4d1d">
               <id root="e80a411d-d802-4611-8894-5627e8acaca3"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Topical ophthalmic solution: bromfenac 0.09%.</paragraph>
               </text>
               <effectiveTime value="20110505"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Topical ophthalmic solution: bromfenac 0.09% <content styleCode="bold">(3)</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_0fcf6d50-576b-4fd4-9eca-054440c1f49a">
               <id root="e3cde422-f9db-4044-ba51-4150f81286f0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20110505"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_precautions_id_1661cc32-fdce-48dd-8476-dc60cae9c0f3">
               <id root="fd5ed72d-774d-4c58-bfd3-b4f36186386a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20180108"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Sulfite Allergic Reactions <content styleCode="bold">(5.1)</content>
                           </item>
                           <item>
                              <caption>•</caption>Slow or Delayed Healing <content styleCode="bold">(5.2)</content>
                           </item>
                           <item>
                              <caption>•</caption>Potential for cross-sensitivity <content styleCode="bold">(5.3)</content>
                           </item>
                           <item>
                              <caption>•</caption>Increase bleeding of ocular tissues <content styleCode="bold">(5.4)</content>
                           </item>
                           <item>
                              <caption>•</caption>Corneal effects including keratitis <content styleCode="bold">(5.5)</content>
                           </item>
                           <item>
                              <caption>•</caption>Contact Lens Wear <content styleCode="bold">(5.6)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_section_id_8171887d-781d-4aba-a932-368437d4eeaf">
                     <id root="b455a8e5-327f-4c32-94a8-a928d1c2fa6f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Sulfite Allergic Reactions</title>
                     <text>
                        <paragraph>Contains sodium sulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_35f170c6-6e09-48a7-b1f0-a6cd0b1b4e9c">
                     <id root="ea2c6d94-1800-4eac-b74b-c9514d8ed446"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Slow or Delayed Healing</title>
                     <text>
                        <paragraph>All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_90009148-958c-4be8-abfe-79f38c52fd61">
                     <id root="7e5794f6-2dea-4343-860b-43094fb2cdc3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Potential for Cross-Sensitivity</title>
                     <text>
                        <paragraph>There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_0d875180-cd94-4b6d-acde-15cc397cfed9">
                     <id root="092f06f0-c6aa-44dc-abfd-d3de9461dc16"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Increased Bleeding Time</title>
                     <text>
                        <paragraph>With some NSAIDs, there exists the potential for increased bleeding time due to interference with platelet aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.</paragraph>
                        <paragraph>It is recommended that bromfenac ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_788215bb-a563-4c97-953d-9a7b92a8f68d">
                     <id root="9136fde9-fb52-4f02-b131-8a9d614f5aa6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Keratitis and Corneal Reactions</title>
                     <text>
                        <paragraph>Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.</paragraph>
                        <paragraph>Post-marketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.</paragraph>
                        <paragraph>Post-marketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for the occurrence and severity of corneal adverse events.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_5b468f58-6ea6-4502-8312-9d86ef6f273f">
                     <id root="551255d5-967d-4b21-80d6-c380dc2913b4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Contact Lens Wear</title>
                     <text>
                        <paragraph>Bromfenac should not be administered while wearing contact lenses. </paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_29e7bb1b-fa2b-4898-a226-8c5b9ffdc6f2">
               <id root="5afe273b-8ff9-4457-a890-2eceb3976a42"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <effectiveTime value="20180108"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most commonly reported adverse reactions in 2-7% of patients were abnormal sensation in eye, conjunctival hyperemia and eye irritation (including burning/stinging) <content styleCode="bold">(6.1)</content>.</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hi-Tech Pharmacal Co., Inc. at 1-800-262-9010 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="i4i_section_id_5619e96f-e5f2-4b16-b129-2b3d0aee8826">
                     <id root="e411ce8f-f298-46f4-b6d9-573624211fd2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph>The most commonly reported adverse experiences reported following use of bromfenac after cataract surgery include: abnormal sensation in eye, conjunctival hyperemia, eye irritation (including burning/stinging), eye pain, eye pruritus, eye redness, headache, and iritis. These events were reported in 2-7% of patients.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_e976511d-3566-4bc8-bae4-aca27c8b254e">
                     <id root="2f663fa3-5500-41f7-a5fb-9b5c03b1d0ff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Post-Marketing Experience</title>
                     <text>
                        <paragraph>The following events have been identified during post-marketing use of bromfenac ophthalmic solution 0.09% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical bromfenac ophthalmic solution 0.09% or a combination of these factors, include corneal erosion, corneal perforation, corneal thinning, and epithelial breakdown. [see <content styleCode="bold">
                              <content styleCode="italics">
                                 <linkHtml href="#i4i_warnings_precautions_id_1661cc32-fdce-48dd-8476-dc60cae9c0f3">Warnings and Precautions</linkHtml> (5)</content>
                           </content>]</paragraph>
                     </text>
                     <effectiveTime value="20180108"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_specific_populations_id_c860bcba-7c35-47f7-bffb-45c16780edc2">
               <id root="a3ff9b0d-605b-42de-b5b7-aff6fc7254cd"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20180108"/>
               <component>
                  <section ID="i4i_pregnancy_id_74dd1c87-daaa-47a1-8ca9-9dc1791a325c">
                     <id root="ef130427-ba53-4d5a-8866-b6dd3b77fb1c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20180108"/>
                     <component>
                        <section ID="i4i_teratogenic_id_0a6e3ee7-446a-40f1-9a83-66b32bb15d0d">
                           <id root="3bbadee9-2d02-44aa-a3e7-f9ddfc8ed5fc"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic Effects</content>
                           </title>
                           <effectiveTime value="20180108"/>
                           <component>
                              <section ID="i4i_pregnancy_C_id_877bb411-b971-4a9f-9ed1-06d474ba14da">
                                 <id root="a675a5f5-1a9b-41fe-9a79-b02ec3b8194f"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="bold">Pregnancy Category C</content>
                                 </title>
                                 <text>
                                    <paragraph>Reproduction studies performed in rats at oral doses up to 0.9 mg/kg/day (1300 times the recommended human ophthalmic dose [RHOD]) and in rabbits at oral doses up to 7.5 mg/kg/day (11,000 times RHOD) revealed no evidence of teratogenicity due to bromfenac. However, 0.9 mg/kg/day in rats caused embryo-fetal lethality, increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated with 7.5 mg/kg/day caused increased post-implantation loss.</paragraph>
                                    <paragraph>There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                                 </text>
                                 <effectiveTime value="20180108"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="i4i_non_teratogenic_id_80f12db8-c80a-4179-8fcc-d72e171e123b">
                           <id root="d81b778f-0b13-45b8-a2b0-8edae088b29d"/>
                           <code code="34078-6" codeSystem="2.16.840.1.113883.6.1" displayName="NONTERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Nonteratogenic Effects</content>
                           </title>
                           <text>
                              <paragraph>Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of bromfenac ophthalmic solution during late pregnancy should be avoided. </paragraph>
                           </text>
                           <effectiveTime value="20180108"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_nursing_mothers_id_72eb40a8-8faf-44e8-9c12-15c77070366f">
                     <id root="96c32e20-5047-4303-a11d-6af6dc28ef49"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Caution should be exercised when bromfenac is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_7b7f6ab3-66d2-4ecb-b2b2-5430168cdd3f">
                     <id root="20ec5b23-c8ab-4594-bf9e-e20a621676ec"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and efficacy in pediatric patients below the age of 18 have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_geriatric_use_id_90aeed83-4601-4079-b754-2985b98209c9">
                     <id root="06a5a991-06b8-4b5e-926c-95fe1f765876"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>There is no evidence that the efficacy or safety profiles for bromfenac differ in patients 65 years of age and older compared to younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_5e692f45-42a2-4723-a912-3b8e31ce2b30">
               <id root="87068f62-53a8-4fab-bd38-aa8784370c2f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Bromfenac ophthalmic solution 0.09% is a sterile, topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Each mL of bromfenac ophthalmic solution contains 1.035 mg bromfenac sodium (equivalent to 0.9 mg bromfenac free acid). Bromfenac sodium is designated chemically as sodium 2-amino-3-(4bromobenzoyl) phenylacetate sesquihydrate, with an empirical formula of C<sub>15</sub>H<sub>11</sub>BrNNaO<sub>3</sub>•1½H<sub>2</sub>O. The structural structure for bromfenac sodium is:</paragraph>
                  <renderMultiMedia ID="id453" referencedObject="id_4eda9186-419f-4087-9a7e-56fcaa6db580"/>
                  <paragraph>Bromfenac sodium is a yellow to orange crystalline powder. The molecular weight of bromfenac sodium is 383.17. Bromfenac ophthalmic solution is supplied as a sterile aqueous 0.09% solution, with a pH of 8.3. The osmolality of bromfenac ophthalmic solution is approximately 300 mOsmol/kg.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each mL of bromfenac ophthalmic solution contains</content>:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Active:</content> bromfenac sodium hydrate 0.1035%</paragraph>
                  <paragraph>
                     <content styleCode="bold">Preservative: </content>benzalkonium chloride (0.05 mg/mL)</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactives:</content>  boric acid, disodium edetate, polysorbate 80, povidone K-30, purified water, sodium borate, and sodium sulfite anhydrous.  Sodium hydroxide may be used to adjust pH. </paragraph>
               </text>
               <effectiveTime value="20180108"/>
               <component>
                  <observationMedia ID="id_4eda9186-419f-4087-9a7e-56fcaa6db580">
                     <text>Chemical Structure_249</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3f300766-1a87-4241-aa89-fb5ee5864248-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_30a240dc-15e5-46c2-bd67-8617be6017a2">
               <id root="55d539df-d069-4c4e-a630-8eceba9e59f7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20110505"/>
               <component>
                  <section ID="i4i_mechanism_action_id_d8424944-81fa-41d4-ae04-a265f910f67e">
                     <id root="f48e0527-5a50-4c62-9fc0-649c8e8c178e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.</paragraph>
                        <paragraph>Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pharmacokinetics_id_51453e2b-27d2-4cd1-8ba8-5ac21d28bf6d">
                     <id root="90e585b1-22c9-4dec-9c81-9d8516037fa3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The plasma concentration of bromfenac following ocular administration of Bromfenac Ophthalmic Solution 0.09% in humans is unknown. Based on the maximum proposed dose of one drop to the eye (0.045 mg) and PK information from other routes of administration, the systemic concentration of bromfenac is estimated to be below the limit of quantification (50 ng/mL) at steady-state in humans.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_nonclinical_toxicology_id_1a3a946c-06ce-4630-8eaa-9e24dc4d7e71">
               <id root="94a557fb-cb2f-4d19-9c50-c6b454763efd"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20110505"/>
               <component>
                  <section ID="i4i_carcinogenesis_mutagenesis_fertility_id_f4e2077b-5ce5-4d32-8e04-82a3fc7209a7">
                     <id root="e888090e-222c-476f-9074-cc70e8ec48d7"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term carcinogenicity studies in rats and mice given oral doses of bromfenac up to 0.6 mg/kg/day (900 times the recommended human ophthalmic dose [RHOD] of 1.67 mcg/kg in 60 kg person on a mg/kg/basis, assuming 100% absorbed) and 5 mg/kg/day (7500 times RHOD), respectively revealed no significant increases in tumor incidence.</paragraph>
                        <paragraph>Bromfenac did not show mutagenic potential in various mutagenicity studies, including the reverse mutation, chromosomal aberration, and micronucleus tests.</paragraph>
                        <paragraph>Bromfenac did not impair fertility when administered orally to male and female rats at doses up to 0.9 mg/kg/day and 0.3 mg/kg/day, respectively (1300 and 450 times RHOD, respectively).</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_studies_id_e05aaeed-eb89-4b37-9954-f12213092b3d">
               <id root="26ce670d-6856-4384-88b7-593e1deeefc7"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20110505"/>
               <component>
                  <section ID="i4i_section_id_5173cb5d-c34a-4e11-ba99-b8a635ab2411">
                     <id root="04575e5f-a416-4a70-8cd4-65e05120fd72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Ocular inflammation and pain following cataract surgery</title>
                     <text>
                        <paragraph>Clinical efficacy was evaluated in three randomized, double-masked, placebo-controlled trials in which subjects requiring cataract surgery were assigned to bromfenac or placebo. Patients were dosed with one drop per eye starting the day before surgery and continuing for 14 days. The primary endpoint was clearing of ocular inflammation by day 15. An additional efficacy endpoint was the number of patients who were pain free on day 1 after cataract surgery. </paragraph>
                        <paragraph>In 2 of the 3 studies, bromfenac ophthalmic solution had statistically significant higher incidence of completely clearing inflammation (46-47% vs. 25-29%) and also had a statistically significant higher incidence of subjects that were pain free at day 1 post cataract surgery (83-89% vs. 51-71%).</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_d2e59baf-b081-421f-ad69-436ec456060b">
               <id root="ff7ff9ad-f3a2-444c-8a6b-7b8d8d0ac46a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Bromfenac Ophthalmic Solution 0.09% is supplied in a white LDPE plastic squeeze bottle with a LDPE white dropper-tip and polypropylene gray cap as follows:</paragraph>
                  <paragraph>1.7 mL in 6 mL container</paragraph>
               </text>
               <effectiveTime value="20130624"/>
               <component>
                  <section ID="i4i_storage_id_d019a647-f797-494f-97a0-e7c145b23c75">
                     <id root="690ae320-48cf-4ec1-81ab-8220b814d37e"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>STORAGE</title>
                     <text>
                        <paragraph>Store at 20º - 25ºC (68º - 77ºF) [see USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20130624"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_info_patients_id_82cb9cbe-41bd-45ec-9349-6eb8204816d1">
               <id root="7f353d17-ccbe-462c-931a-1e5fee1abcc5"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20180108"/>
               <component>
                  <section ID="i4i_section_id_343b6913-426d-4864-b5bf-d4529bab1de0">
                     <id root="8e76e090-0bb0-4844-b20c-5ba40b4936ff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.1 Slowed or Delayed Healing</title>
                     <text>
                        <paragraph>Patients should be advised of the possibility that slow or delayed healing may occur while using NSAIDs.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_f7acd7ad-6e79-423c-99a6-2a0887215568">
                     <id root="0fa52261-b147-4e29-9965-18a173e516b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.2 Sterility of Dropper Tip</title>
                     <text>
                        <paragraph>Patients should be advised to not touch dropper tip to any surface, as this may contaminate the contents.</paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_57d228cd-9c25-4f39-8964-a34cff162eec">
                     <id root="5e398155-f6c0-4fc1-8c6f-c1273c7053e3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.3 Concomitant Use of Contact Lenses</title>
                     <text>
                        <paragraph>Contact lenses should not be worn during the use of this product. </paragraph>
                     </text>
                     <effectiveTime value="20110505"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_section_id_61231c67-e101-49f7-b4c1-48b8d2815625">
                     <id root="f3999c85-16c5-499d-92c9-6cfb594163e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>17.4 Concomitant Topical Ocular Therapy</title>
                     <text>
                        <paragraph>If more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Rx Only</content>
                        </paragraph>
                        <paragraph>Manufactured by:</paragraph>
                        <paragraph>Hi-Tech Pharmacal Co., Inc.</paragraph>
                        <paragraph>Amityville, NY  11701</paragraph>
                        <paragraph>Rev. 249:01 6/13</paragraph>
                        <paragraph>MG #30851</paragraph>
                     </text>
                     <effectiveTime value="20180108"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_Principal_display_panel_id_86591c3b-6139-4b89-bf7f-c0b5a15e59d7">
               <id root="74c4b924-dd31-4026-8f34-33333ef47c2d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia ID="id-132560419" referencedObject="ID_6ff47671-4427-4778-b9f7-098954aba0c6"/>
                  <paragraph>AKORN</paragraph>
                  <paragraph>NDC 50383-249-71</paragraph>
                  <paragraph>
                     <content styleCode="bold">Bromfenac Ophthalmic Solution, 0.09%</content>
                  </paragraph>
               </text>
               <effectiveTime value="20180108"/>
               <component>
                  <section ID="id_da4f677c-234a-4ba7-aa55-503e44fc5841">
                     <id root="48ad1140-c514-48e5-8c04-9192174f27e2"/>
                     <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="Boxed Warning section"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Once Daily</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20180108"/>
                  </section>
               </component>
               <component>
                  <section ID="id_ae6821f1-7b2f-4bdc-85c2-cd24f67dd9a3">
                     <id root="ae6821f1-7b2f-4bdc-85c2-cd24f67dd9a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">For topical application in the eye.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Rx only</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Sterile</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">1.7 mL</content>
                        </paragraph>
                        <paragraph> </paragraph>
                        <paragraph> </paragraph>
                     </text>
                     <effectiveTime value="20130624"/>
                  </section>
               </component>
               <component>
                  <observationMedia ID="ID_6ff47671-4427-4778-b9f7-098954aba0c6">
                     <text>carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>